Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LOTIS-3: loncastuximab tesirine plus ibrutinib in advanced DLBCL or MCL
2018-002625-38Phase 2Completed
- Sponsor
- ADC Therapeutics
- Start
- Oct 2018
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of loncastuximab tesirine and ibrutinib in diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL), sponsored by ADC Therapeutics. Primary endpoint: Safety and tolerability (Phase 1). Started Oct 2018; status: completed.
02
Drugs
loncastuximab tesirineibrutinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on 2018-002625-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002625-38.